Beam Looks Beyond Liver With Guide Therapeutics Acquisition

Company Pays $120m Upfront

 
• By Alaric DeArment

Beam Therapeutics said acquiring Guide Therapeutics' IP could enable LNP delivery of gene-editing payloads to tissues other than the liver.

Genetic engineering and gene manipulation concept. Hand is replacing part of a DNA molecule. 3D rendered illustration of DNA.
Beam Therapeutics acquires Guide Therapeutics for $120m upfront and up to $320m in milestones. • Source: Shutterstock

More from R&D

More from Scrip